Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsCGRP therapies revolutionized migraine treatment, but many patients still don't get relief — and researchers are hunting for what comes next. From PACAP-blocking antibodies to ion-channel modulators and amylin, a new wave of targets is entering clinical testing. The future of migraine care may look less like one-size-fits-all and more like personalized, multi-pathway treatment.
CGRP-targeting therapies — monoclonal antibodies and gepants — have been a game-changer for migraine patients over the past decade. But a significant portion of patients still don't respond, lose benefit over time, or only partially improve. That gap is pushing researchers to explore a broader map of migraine biology, with several new targets now in active clinical development.
Leading the charge is PACAP (pituitary adenylate cyclase-activating polypeptide), a neuropeptide that operates through distinct receptors and signaling pathways from CGRP. The anti-PACAP antibody bocunebart has shown promising — if modest — results in phase 2/2b trials among patients who had previously failed preventive treatments. Crucially, PACAP can trigger migraines even when CGRP is blocked, suggesting it taps into a parallel pathway. Beyond PACAP, ion channels (TRPM3, TRPM8, KATP, BK) and amylin are emerging as additional targets, with early human provocation studies and phase 2 trials underway.
Key Takeaways:
Why it matters: Migraine affects over a billion people globally, and current therapies leave many undertreated. A multi-target, individualized approach — potentially combining sequential therapies across different biological pathways — could finally close that gap.
